Fibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis

B Selvarajah, I Azuelos, D Anastasiou… - Science Signaling, 2021 - science.org
Fibrosis is the final pathological outcome and major cause of morbidity and mortality in many
common and chronic inflammatory, immune-mediated, and metabolic diseases. Despite the …
被引用次数：47 相关文章

Fibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis.

B Selvarajah, I Azuelos, D Anastasiou… - Science …, 2021 - search.ebscohost.com
Fibrosis is the final pathological outcome and major cause of morbidity and mortality in many
common and chronic inflammatory, immune-mediated, and metabolic diseases. Despite the …

Fibrometabolism-An emerging therapeutic frontier in pulmonary fibrosis.

B Selvarajah, I Azuelos, D Anastasiou… - Science …, 2021 - europepmc.org
Fibrosis is the final pathological outcome and major cause of morbidity and mortality in many
common and chronic inflammatory, immune-mediated, and metabolic diseases. Despite the …

Fibrometabolism-An emerging therapeutic frontier in pulmonary fibrosis

B Selvarajah, I Azuelos, D Anastasiou… - Science …, 2021 - pubmed.ncbi.nlm.nih.gov
Fibrosis is the final pathological outcome and major cause of morbidity and mortality in many
common and chronic inflammatory, immune-mediated, and metabolic diseases. Despite the …

Fibrometabolism-An emerging therapeutic frontier in pulmonary fibrosis

B Selvarajah, I Azuelos, D Anastasiou… - Science …, 2021 - discovery.ucl.ac.uk
Fibrosis is the final pathological outcome and major cause of morbidity and mortality in many
common and chronic inflammatory, immune-mediated, and metabolic diseases. Despite the …